Group 1: Investor Relations Activity Overview - The company held an earnings briefing on May 8, 2025, via the China Securities Roadshow Center [4] - Participants included the company's chairman, vice chairman, and board secretary [4] Group 2: Sales Performance and Market Strategy - In 2024, domestic sales revenue reached 37,235.67 million CNY, accounting for 69.32% of total revenue, while export revenue was 16,477.95 million CNY, making up 30.68% [6] - The company plans to mitigate policy risks by optimizing management, reducing costs, and expanding market reach [6] Group 3: Product Development and Market Impact - The "40 tons of Lopinavir and 60 tons of Rufinamide API construction project" was completed and is expected to positively impact operations once products are marketed [6] - Rufinamide has been registered in over ten European countries, while Lopinavir's domestic registration is under review, with expected approval within the year [6] Group 4: Future Growth Strategy - The company aims to focus on refining APIs, expanding new materials, specializing in intermediates, and developing generic and innovative drugs [7] - Strategies include enhancing product quality to maintain market share and investing in R&D for new API development [7] - The company will implement a "dual circulation" strategy to expand both domestic and international markets [7]